# OnCo record alx-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/alx-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "alx-oncology" ;
  schema:name "ALX Oncology"@en ;
  schema:alternateName "ALX Oncology Holdings"@en ;
  schema:description "ALX Oncology is a Californian biotechnology company developing evorpacept, a CD47-blocking fusion protein designed to remove the 'do not eat me' signal so that antibodies such as trastuzumab can recruit macrophages against HER2-positive gastric cancer."@en ;
  schema:url <https://onco.cc/companies/alx-oncology/>, <https://alxoncology.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://alxoncology.com/>, <https://clinicaltrials.gov/search?lead=ALX%20Oncology> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:targets <https://onco.cc/targets/cd47/> ;
  onco:drugs <https://onco.cc/drugs/evorpacept/> ;
  onco:trials <https://onco.cc/trials/aspen-06/>, <https://onco.cc/trials/nct04675294/>, <https://onco.cc/trials/nct04675333/>, <https://onco.cc/trials/nct07007559/> .